Next Article in Journal
Assessing the Value of Delandistrogene Moxeparvovec (SRP-9001) Gene Therapy in Patients with Duchenne Muscular Dystrophy in the United States
Previous Article in Journal
Artificial Intelligence and Remote Patient Monitoring in US Healthcare Market: A Literature Review
 
 
Journal of Market Access & Health Policy (JMAHP) is published by MDPI from Volume 12 Issue 1 (2024). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Taylor & Francis.
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Quantitative Revenue Estimates and Qualitative Assessments of Innovative Fundraising Sources for Treating Rare Diseases in Colombia

by
Surrey M Walton
1,*,
Wilson Mayorga
2,
Angela Rodríguez Narváez
3,
Maria Alejandra Chavez
4,
Natalia Cortés Guesguán
3,†,
Luis Durango
5 and
Ludy Alexandra Parada
5
1
Managing Partner, Second City Outcomes Research LLC, Oak Park, IL, USA
2
Actuary Manager, Numeris, Bogota, Colombia
3
Economist, Numeris, Bogota, Colombia
4
Researcher, IQVIA, Bogota, Colombia
5
Public Policy Team, Roche, Bogota, Colombia
*
Author to whom correspondence should be addressed.
Changed to Data Analytics, Transunion (Cifin).
J. Mark. Access Health Policy 2023, 11(1), 2211868; https://doi.org/10.1080/20016689.2023.2211868
Submission received: 3 February 2023 / Revised: 1 May 2023 / Accepted: 5 May 2023 / Published: 11 May 2023

Abstract

Background: Like many developing countries, Colombia faces difficulties in financing health-care services as well as programs for health promotion and health education and there is evidence that its health-care system is underperforming. Objective: To provide evidence-based estimates of potential funding levels and assess the strengths, weaknesses, and viability of innovative funding mechanisms with a focus on treating rare diseases in Colombia. Methods: The strategy involved evidence-based projections of potential funding levels and a qualitative viability assessment using an expert panel. Results: Crowdfunding, corporate donation, and social impact bonds (SIBs) were deemed to be the most viable of numerous potential strategies. Expected funding levels over 10 years for rare diseases in Colombia from crowdfunding, corporate donations, and SIBs were roughly $7,200, $23,000, and $12,400, respectively. Conclusions: Based on the combination of projected funding potential along with expert consensus regarding viability and operability, crowdfunding, corporate donations, and SIBs, especially in combination, have the potential to substantially improve funding for vulnerable patient populations in Colombia.
Keywords: innovative; fundraising; rare disease; Colombia innovative; fundraising; rare disease; Colombia

Share and Cite

MDPI and ACS Style

Walton, S.M.; Mayorga, W.; Narváez, A.R.; Chavez, M.A.; Guesguán, N.C.; Durango, L.; Parada, L.A. Quantitative Revenue Estimates and Qualitative Assessments of Innovative Fundraising Sources for Treating Rare Diseases in Colombia. J. Mark. Access Health Policy 2023, 11, 2211868. https://doi.org/10.1080/20016689.2023.2211868

AMA Style

Walton SM, Mayorga W, Narváez AR, Chavez MA, Guesguán NC, Durango L, Parada LA. Quantitative Revenue Estimates and Qualitative Assessments of Innovative Fundraising Sources for Treating Rare Diseases in Colombia. Journal of Market Access & Health Policy. 2023; 11(1):2211868. https://doi.org/10.1080/20016689.2023.2211868

Chicago/Turabian Style

Walton, Surrey M, Wilson Mayorga, Angela Rodríguez Narváez, Maria Alejandra Chavez, Natalia Cortés Guesguán, Luis Durango, and Ludy Alexandra Parada. 2023. "Quantitative Revenue Estimates and Qualitative Assessments of Innovative Fundraising Sources for Treating Rare Diseases in Colombia" Journal of Market Access & Health Policy 11, no. 1: 2211868. https://doi.org/10.1080/20016689.2023.2211868

Article Metrics

Back to TopTop